BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230208
DTEND;VALUE=DATE:20230210
DTSTAMP:20260515T234251
CREATED:20221025T104610Z
LAST-MODIFIED:20221025T104610Z
UID:35615-1675814400-1675987199@www.pharmajournalist.com
SUMMARY:14th Annual RNA Therapeutics Conference
DESCRIPTION:SAE Media Group invites you to join the 14th Annual RNA Therapeutics Conference\, taking place on 8 and 9 February 2023\, in London\, UK. \nBuilding on the success of previous years\, the RNA Therapeutics Conference will bring together industry experts from leading pharma and biotech companies to provide an expert and holistic view on the latest developments of the industry. \nRNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy\, personalised medicines\, and treatment of genetic\, infectious and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025\, growing at a CAGR of 7.5%. \nWith Covid-19 rapidly accelerating the RNA landscape through massive regulatory successes\, the recent advent of CRISPR\, an RNA-guided gene-editing technology\, as well as new strides in the delivery of messenger RNA transcribed in vitro\, there has been considerable progress in the development of RNA medicines and a major expansion of the RNA-therapeutics field. \nThis year’s conference will reflect on how the industry has adapted and played a pivotal role in global health over the past year and will discuss the takeaways for future mRNA therapeutic development. \nBenefits of attending: \n\nExplore how mRNA leads the way in the genetic medicine space as the next generation of novel drug modalities\nInvestigate the latest trends in AI drug discovery as a tool for designing novel RNA based therapeutics\nEnhance your knowledge of the latest innovations in RNA application and RNA delivery techniques with case studies from BioNTech\, Neuway Pharma and Ethris GmbH\nEngage in the growing advances and development of novel RNA molecules in the treatment of chronic respiratory\, neurodegenerative\, and infectious diseases\n\nWho should attend: \n\nDirectors of novel RNA therapies\nCEOs\nSenior and expert scientists\nChief Medical Officers\nChief Technical Officers\nSenior Vice Presidents\nGlobal Heads of mRNA R&D\nGlobal Medical Directors\nHeads of Translational Medicine\nDirector\, Clinical Pharmacology\nGlobal Head of RNA and Targeted Therapeutics\nClinical Science Director\nHead of Biology\nDirector\, Genetic Medicine\nAssociate Director\n\nEARLY-BIRD RATES: \n\nREGISTER BY 31ST OCTOBER AND SAVE £400\nREGISTER BY 3OTH NOVEMBER AND SAVE £200\nREGISTER BY 16TH DECEMBER AND SAVE £100
URL:http://www.pharmajournalist.com/event/14th-annual-rna-therapeutics-conference/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:lamprini.balasi@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230202
DTEND;VALUE=DATE:20230203
DTSTAMP:20260515T234251
CREATED:20221208T120155Z
LAST-MODIFIED:20221208T120155Z
UID:36005-1675296000-1675382399@www.pharmajournalist.com
SUMMARY:Cancer Neoantigen Vaccines
DESCRIPTION:Over the last few decades\, immunotherapy has developed at a rapid rate in the treatment of cancer where neoantigens are the latest breakthrough in tumour immunotherapy. Today\, it is still unclear when a cancer vaccine will be made commercially available; what is the latest academic research showing us? What is the industry missing and where are we going? \nJoin us through a series of inspiring keynote presentations and engaging panel discussions to connect with top pioneers in the space\, to discuss the future of cancer immunotherapy and how neoantigens are transforming the field. \nUnlock the new era of vaccine development at Cancer Neoantigen Vaccines\, a 1-day digital conference taking place February 2\, 2023 and discover the path to commercial success with novel approaches toward cancer neoantigen vaccines. \nYou’ll shape the future of next generation cancer vaccine development with new oncolytic approaches and critical immunotherapy strategies and uncover\, key research on targets and evolution\, how to successfully enter global markets and the future of personalisation and beyond. \nYou can expect to uncover methods of identifying true targets and deep dive into the future of machine and deep learning in identifying neoantigens. Plus\, you’ll hear successful case studies and promising data on the latest neoantigen vaccine development and gain a deeper understanding of the future of vaccines in personalised medicine. Don’t miss your opportunity to be a part of the discussions with industry experts on their look to the future. \nAll of this plus much more without leaving your desk! Your digital pass gives you access to the full attendee list with video chat\, instant message\, and meeting request functionalities to connect with like-minded thought-leaders in the field to expand your network\, and access to the content on-demand for 10 working days post-event.
URL:http://www.pharmajournalist.com/event/cancer-neoantigen-vaccines/
LOCATION:Digital Conference
ORGANIZER;CN="Informa Connect":MAILTO:Danielle.horney@informa.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230130
DTEND;VALUE=DATE:20230202
DTSTAMP:20260515T234251
CREATED:20221121T083953Z
LAST-MODIFIED:20221121T083953Z
UID:35900-1675036800-1675295999@www.pharmajournalist.com
SUMMARY:3rd TGF-β for Immuno-Oncology Drug Development Summit
DESCRIPTION:Exploit Understanding of TGF-β Biology\, Harness Clinically Validated Biomarkers & Advance Safe & Efficacious Clinical Programs for Maximal Therapeutics Benefit in Immuno-Oncology. \nIn the past year alone\, the field has learnt valuable lessons from the clinical trials and from the wider TGF-β field that will equip the immuno-oncology field with the knowledge needed to supercharge future TGF-β monotherapy or combinational therapeutics for precision medicine. \nFrom uncovering the effects and production of TGF-β in immune\, tumor and stromal cells to exploring predictive and pharmacodynamic TGF-β biomarkers for patient identification and assessing the clinical challenges that led to recent clinical failures\, the 3rd TGF-β for Immuno-Oncology Drug Development Summit is your one-stop-shop dedicated to harnessing you with the knowledge to unlock the potential of successfully targeting TGF-β. \nTailored with 18+ senior leaders\, the 2023 meeting will be taking place in-person for the first time – don’t miss your chance to be in the room for your comprehensive guide on TGF-β in immuno-oncology! \nWhether you are new to this field or a seasoned expert\, this meeting will provide you with the must-know takeaways from the basic biology to biomarkers to clinical trial design to overcome the clinical setbacks and produce a blockbuster TGF-β therapeutic. \nTo know more visit: https://ter.li/cjnpgy
URL:http://www.pharmajournalist.com/event/3rd-tgf-%ce%b2-for-immuno-oncology-drug-development-summit/
LOCATION:Marines Memorial Club and Hotel\, 609 Sutter St\, San Francisco\, CA\, 94102\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230124
DTEND;VALUE=DATE:20230127
DTSTAMP:20260515T234251
CREATED:20221110T115619Z
LAST-MODIFIED:20221110T115619Z
UID:35763-1674518400-1674777599@www.pharmajournalist.com
SUMMARY:2nd HFpEF & HCM Drug Discovery & Development Summit
DESCRIPTION:The 2nd HFpEF & HCM Drug Discovery & Development Summit is the definitive industry forum dedicated to propelling drug discovery and development across emerging therapeutics including cell and gene therapies and the implementation of precision medicine. \n \nShake hands with industry pioneers prioritizing the development of therapeutic treatments to complement the new standard of care with SGLT2 inhibitors and understand how you can leverage advances in biomarkers for early detection of drug efficacy and clinical trial updates to inform your strategic decisions. \nJoin 80+ biopharma experts in research\, cardiovascular\, rare disease and precision medicine as they analyze the HFpEF patient population and translational drug development pathway to achieve new commercially viable and clinically accepted therapeutics. \nTo know more visit: https://bit.ly/3EjK5H3
URL:http://www.pharmajournalist.com/event/2nd-hfpef-hcm-drug-discovery-development-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230124
DTEND;VALUE=DATE:20230127
DTSTAMP:20260515T234251
CREATED:20221011T104423Z
LAST-MODIFIED:20221208T115612Z
UID:35446-1674518400-1674777599@www.pharmajournalist.com
SUMMARY:DDR Inhibitors Summit 2023
DESCRIPTION:The 6th DDR Inhibitors Summit is taking place in-person for the first time in 3 years in Boston\, MA this January 24 – 26\, 2023. \nThe DNA damage response inhibitor space only continues to grow\, with progress being accelerated by a shift in focus onto next-generation targets like PolQ and WRN\, moving forward from monotherapies through combining targets and exploiting sensitivity caused by DDRis to enhance other therapies like radiotherapy. \nThe scope of this year’s meeting is to bring together leading minds in DDRi drug development to exploring these strategies and aim to address issues related to emerging DDR inhibitor resistance and maximizing efficacy\, as well as addressing the biggest challenge in the space right now\, toxicity. \nThe 3-day meeting will consist of a comprehensive overview of the DDR space\, with over 30+ world class speakers sharing insights preclinical updates\, progress in the clinic\, solutions to overcoming toxicity and improving patient selection. \nDon’t miss out on hearing from the best in the field on how to overcome toxicity and resistance during drug design as well as in the clinic\, to maximize efficacy and propel your DDR inhibitors to success. \nTo know more visit: https://ter.li/40qr50
URL:http://www.pharmajournalist.com/event/ddr-inhibitors-summit-2023/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230124
DTEND;VALUE=DATE:20230127
DTSTAMP:20260515T234251
CREATED:20220826T121137Z
LAST-MODIFIED:20220831T191624Z
UID:35017-1674518400-1674777599@www.pharmajournalist.com
SUMMARY:2nd Annual mRNA-Based Therapeutics Summit Europe
DESCRIPTION:The 2nd Annual mRNA-Based Therapeutics Summit Europe is the only end-to-end mRNA-dedicated meeting in Europe and the largest gathering for mRNA professionals outside of the United States. \nBuilt with biopharmaceutical industry insights\, this meeting will unite KOLs from Europe and the rest of the world to delve into the challenges associated with successfully designing and developing the next-generation of mRNA-based vaccines & therapeutics with improved specificity\, delivery & efficacy for immuno-oncology\, infectious diseases and beyond. \nHear from 35+ pioneering large pharma\, biotech\, and academic experts who are shaping the landscape of mRNA-based therapeutics and discover how they are addressing the major challenges facing the industry. \nWith more companies investing in their tools and technologies to innovate processes and technologies to address key challenges such as sequence optimization\, cell-specific payload expression\, and durability\, there has never been a more pivotal time to join European biopharma experts and discuss the following topics. \n-Emerging cell-enhancing or protein replacement therapies based on mRNA \n-Optimization of analytical and quality control protocols \n-Durability\, accessibility and immunogenicity challenges of mRNA therapeutics and vaccines \n-Enhancement of formulation\, process development and manufacturing processes \n-Need for clear regulatory path to support the technology whilst enabling speed to market \nTo learn more\, download your copy of the full event guide including all speakers and their session details: https://ter.li/tholw0
URL:http://www.pharmajournalist.com/event/2nd-annual-mrna-based-therapeutics-summit-europe/
LOCATION:TBC – Berlin\, Germany
ORGANIZER;CN="Hanson Wade":MAILTO:mailto:info@hansonwade.com?subject=2nd Annual mRNA-Based Therapeutics Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230123
DTEND;VALUE=DATE:20230125
DTSTAMP:20260515T234251
CREATED:20221007T091733Z
LAST-MODIFIED:20221007T091733Z
UID:35438-1674432000-1674604799@www.pharmajournalist.com
SUMMARY:Transdermal and Microneedle Drug Delivery
DESCRIPTION:SAE Media Group’s 2nd Annual Conference \nTransdermal and Microneedle Drug Delivery \nJanuary 23 – 24\, 2023 | London\, UK \nwww.transdermal-microneedle-delivery.co.uk/pharmajournalistel \n————————————————————————- \nSAE Media Group is proud to present the 2nd annual Transdermal and Microneedle Drug Delivery Conference\, taking place on the 23rd to 24th January 2023. \n \nThe 2023 Transdermal and Microneedle Drug Delivery Conference will explore real world applications of microneedles in drug delivery and strategies for advanced and user-centric device design. Regulation of transdermal delivery systems will be another key theme addressed\, in combination with clinical trial optimization. Engage in the latest innovations in device design\, development and formulation\, with case studies from expert key opinion leaders of this rapidly accelerating space. Other key areas will be microneedle vaccines and transdermal patches for management of chronic disease. \nThe two-day agenda offers you peer-to-peer networking with CEO’s\, Senior Vice presidents\, Directors\, Heads of Product Development and many more. \nBENEFITS OF ATTENDING: \n\nEngage with senior industry opinion leaders presenting their experiences and case studies in innovative device design and advanced drug product formulation\nGain insights from notified body and competent authority representatives addressing key regulatory requirements\nUnderstand how to optimize your lifecycle management strategy for a commercially successful device\nExplore and benchmark against industry advances in device design through case studies and real-world examples\n\nWHO SHOULD ATTEND: \n\nDrug-Delivery Device Developers\nMicroneedle Device Developers\nTransdermal Delivery Developers\nMicroarray Patch Developers\nMedical Device Engineers\nPrimary Packaging Material Designers\nSecondary Packagers\nSmart Device Developers\nTraining Device Developers\nDevice-Safety Solution Providers\nDrug Developers\nTransdermal Drug Product Developers\n\nEARLY-BIRD RATES:  \n\nBOOK BY 30TH SEPTEMBER AND SAVE £400\n\nRegistrations can be made on the event website at: www.transdermal-microneedle-delivery.co.uk/ \nTargeted Keywords \nTransdermal and Microneedle Drug Delivery\, transdermal\, drug development\, regulatory guidelines\, pharmaceutical industry\, drug delivery\, therapeutic sectors\, vaccines\, Parenteral administration\, combination products\, primary packaging\, sterile injectables\, connectivity\, human factors\, autoinjectors
URL:http://www.pharmajournalist.com/event/transdermal-and-microneedle-drug-delivery/
LOCATION:London\, UK
ORGANIZER;CN="SAE Media Group":MAILTO:RJones@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230117
DTEND;VALUE=DATE:20230120
DTSTAMP:20260515T234251
CREATED:20221021T090337Z
LAST-MODIFIED:20221021T090337Z
UID:35537-1673913600-1674172799@www.pharmajournalist.com
SUMMARY:Spatial Biology for Immuno-Oncology Summit
DESCRIPTION:The inaugural Spatial Biology for Immuno-Oncology Summit runs at a crucial moment in time. Spurred on by technological advancement and successful case studies\, spatial technologies are set to become increasingly mainstream and accessible. If you’re not already\, now is the time to harness spatial technologies to power your immunotherapy research\, improve your clinical trials\, enhance your biomarker discovery\, and streamline your therapeutic development. \nUniting researchers\, technology providers\, and drug developers\, next January join your peers to hear the latest best-practice case studies on operationalizing technology\, integrating spatial into the clinic\, and developing a robust data analysis pipeline. This meeting will provide an unrivaled opportunity to solve your current spatial challenges to improve your ability to treat disease and identify drug targets in immuno-oncology. \nAcross 3 jam-packed days of content\, led by 20+ immuno-oncology leaders\, the Spatial Biology for Immuno-Oncology Summit is your only chance to discover how technologies that put omics and single-cell information in spatial context can improve your ability to treat disease and identify drug targets in immuno-oncology. \nJoin over 100 key industry stakeholders as they gather and leave no stone unturned to advance the application of this revolutionary technology. \nTo know more visit: https://bit.ly/3yYeUhw
URL:http://www.pharmajournalist.com/event/spatial-biology-for-immuno-oncology-summit/
LOCATION:The Westgate Hotel\, 1055 2nd Ave\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230116
DTEND;VALUE=DATE:20230118
DTSTAMP:20260515T234251
CREATED:20220926T093554Z
LAST-MODIFIED:20220926T100546Z
UID:35289-1673827200-1673999999@www.pharmajournalist.com
SUMMARY:11th Annual Pharmaceutical Microbiology Conference
DESCRIPTION:11th Annual Pharmaceutical Microbiology Conference  \n16 – 17 January 2023 \nLondon\, UK\nhttp://www.pharma-microbiology.com/PJwl \n Sponsored by: Microgenetics  \nCo-chairs Di Morris\, Clinical Auditor\, AstraZeneca and Nigel Cryer\, Deputy Director Global Audit\, Sanofi  \nHarnessing Alternative Rapid Microbial Methods for a Successful Contamination Control Strategy  \n \nWe are delighted to announce SAE’s 11th Annual Pharmaceutical Microbiology Europe Conference taking place in London\, UK on the 16-17 January 2023. \nMicrobiology remains an essential tool for the detection of microorganisms present in biopharmaceutical and pharmaceutical batches. This conference will explore the most pressing topics in this thriving field\, from the movement toward process automation and increased regulatory stringency\, to the latest technologies in rapid microbiological testing methods and data integrity. \nEvent Hashtag: #MicrobiologyEurope \nKey Highlights for 2023 Conference: \n\nOptimise your contamination control strategy and review the initial impact of Annex 1\nLearn how to utilise the latest microbiological methods to modernise your contamination control strategy\nMaximise the data output from your environmental and microbial monitoring with proven strategies and technologies\nIncrease the diversity of your testing methodologies through industry case studies including the recombinant factor C assay and Monocyte Activation Test\n\nWho Should Attend? \nHeads of Microbiology\, Heads of Aseptic Processing\, Global Quality Directors\, Heads of GMP Compliance\, Quality & Compliance Heads\, Microbiology Senior Specialists\, Directors of Quality Control Biology\, Quality Control Managers\, Quality Assurance Managers\, Lean Managers\, Operations Managers\, Heads of Site Compliance\, Heads of Sterile Technology\, Global Microbiology Analytical Experts\, Cleanroom Managers\, Regulatory Affairs Managers\, Production Managers\, Quality Systems Managers \nDownload the brochure at: http://www.pharma-microbiology.com/PJwl
URL:http://www.pharmajournalist.com/event/11th-annual-pharmaceutical-microbiology-conference/
LOCATION:London\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230110
DTEND;VALUE=DATE:20230113
DTSTAMP:20260515T234251
CREATED:20221007T084856Z
LAST-MODIFIED:20221007T084856Z
UID:35427-1673308800-1673567999@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes and Injectable Drug Devices Europe
DESCRIPTION:SAE Media Group’s 15th Annual Conference \nPre-Filled Syringes and Injectable Drug Devices Europe \nJanuary 10 – 12 2023 | London\, UK \nhttp://www.pre-filled-syringes.com/pharmajournalist \n————————————————————————- \nThe pre-filled syringes industry is growing at an exponential rate with innovations in parenteral delivery device development to increase patient centricity\, aid self-administration and deliver biologics that have large-volumes and novel formulations. This year’s conference will explore the exciting advances in the combination product drug delivery space and a future outlook exploring how pharma\, device developers and regulators can work together to encourage innovation. \n \nSAE Media Group’s 15th Annual Pre-Filled Syringes and Injectable Drug Devices Conference will be bigger than ever\, with a pre-conference focus day exploring the advances in PFS design for enhanced drug delivery proceeded by a two-day main conference comprising of morning keynote plenaries and parallel afternoon topic streams as detailed below: \n\nNovel Drug Products and Large Volume Delivery\nSustainability for Injectable Delivery Devices\nPrimary Packaging Development\nConnected Drug Delivery Devices\n\nTopics of discussion will include the latest updates in the combination product regulatory framework\, insights into the evolving digital health landscape for connected delivery devices\, considerations for the development of primary packaging\, utilising platform technology\, the delivery of novel drug formulations and large volume drug products\, patient centric approaches to device design as well as sustainable approaches for device development. \nThis event will not only bring you key insights you need to expand and enhance your injectable device portfolio but will also give you the opportunity to network with key players throughout the industry. \nBenefits of Attending: \n\nEngage with industry representatives on the latest trends within the pre-filled syringe and injectable device market\nHear about new technological advances in the delivery of large volume drugs\nExplore updates to drug device combination product design approaches considering patient preference at the forefront with case studies from big pharma representatives\nUnderstand the latest regulatory requirements from regulatory experts surrounding medical devices and digital health\nDelve into the considerations for material components for the development of primary packaging\nGain insight into how big pharma are incorporating sustainable approaches into drug device design\n\nWho should attend: \nAdvanz Pharma; AstraZeneca; Balda Medical GmbH & Co. KG; Bayer AG; Bayer Pharma; BD Medical; BD Medical – Pharmaceutical Systems; Becton Dickinson (BD); Boehringer Ingelheim; Boehringer Ingelheim GmbH & Co. KG; Boehringer Ingelheim Pharma GmbH & CO KG; Boehringer Ingelheim Pharma Gmbh & Co. Kg; BSI; BSI Group; Chiesi Ltd; Crux Product Design Ltd; DCA Design International; Device Development; Dr.Reddys; GlaxoSmithKline; GSK; Hoffmann-La Roche; Horizon Therapeutics GmbH; Ichnos Sciences; Janssen Pharmaceutical Companies; Johnson & Johnson; Johnson & Johnson (Janssen Pharmaceutical); Medincell; Merck Group; Midas Pharma Gmbh; Nemera; Novartis; Novo Nordisk; Novo Nordisk A/S; Owen Mumford; Pfizer; Pfizer UK; PharmaEssentia; Prescient Healthcare Group; RAUMEDIC AG; Sanofi; SCHOTT AG; SPM MEDICARE PVT LTD\, INDIA; Sustainable Healthcare Coalition; Takeda; Teva; Teva Pharmaceuticals; Teva Pharmaceuticals Industries Ltd.; Teva\, Combination Products; TUV Italia SRL; TUV SUD Japan Ltd.; TUV SUD Product Service GmbH; University of Liverpool; University of Southern Denmark; Zeon Europe GmbH; Zeon Specialty Materials ; \nSAE Media Group offer direct access to key decision makers through tailored sponsorship and exhibitor packages. \nFor details\, please contact Daniele Moreschi on: +44 (0)20 7827 6050 or dmoreschi@smi-online.co.uk \nFor all delegate enquiries\, contact Jamie Wilkinson on: +44 (0) 20 7827 6136 or jwilkinson@smi-online.co.uk \nAbout SAE Media Group Conferences: \nSAE Media Group Conferences connects global communities with focused networking conferences. We provide our customers with solutions through industry knowledge and collaboration that enables our attendees to return to their organisations better equipped to overcome their key business challenges. Our key events focus on Defence and Aerospace\, Pharmaceutical and Medical.  Each year we bring together over 5\,000 senior business professionals at our conferences. http://www.smgconferences.com \nSAE Media Group (SMG)\, a subsidiary of SAE International\, reports the latest technology breakthroughs and design innovations to a global audience of nearly 1\,000\,000 engineers\, researchers\, and business managers. SMG provides critical information these professionals need to develop new and improved products and services.
URL:http://www.pharmajournalist.com/event/pre-filled-syringes-and-injectable-drug-devices-europe/
LOCATION:London\, UK
ORGANIZER;CN="SAE Media Group":MAILTO:RJones@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221214
DTEND;VALUE=DATE:20221215
DTSTAMP:20260515T234251
CREATED:20221018T101336Z
LAST-MODIFIED:20221018T105122Z
UID:35527-1670976000-1671062399@www.pharmajournalist.com
SUMMARY:PURIFY – Chromatography Purification Conclave
DESCRIPTION:PURIFY Conclaves are pioneers of dedicated conferences in India that will help stretch possibilities\, be it discovery\, development or scaleups! \nThe pharmaceutical industry continues to dwell deeper into the growing possibilities for chromatography purification; the PURIFY conclaves touches upon diverse aspects of chromatography purification. \nThe attendees at PURIFY get exposed to a myriad of topics that could change the way they work…change the way they purify. New separation techniques and approaches\, niche topics\, deeper understanding of preparative and process chromatography and allied fields\, and upcoming application areas that will provide quality substance to the discerning scientists. So\, if you wish to get that additional gram\, which is purer\, in as less a time\, with minimal resources…there will surely be something for you at PURIFY conclaves! \nThe annually occurring PURIFY Conclave is an initiative by Custage Marketing Solutions LLP\, a Mumbai based company. \nThe PURIFY conclave is attended by analytical and research chemists\, scientists with scale-up and process development knowledge\, managers\, group heads\, natural product purification experts\, experts from quality and manufacturing\, academicians\, policy makers\, supply chain heads etc. of this pharmaceutical – APIs\, peptides\, proteins\, oligonucleotides\, chiral molecules\, bio-pharmaceutical\, fine chemicals\, environmental studies\, food and beverage\, polymers\, biotechnology\, cosmetics and fragrance to understand the advancements in chromatography platforms. \nSo\, the purification expert in you will surely get answers to the daily challenges faced for you in your laboratories. And what’s more\, the knowledge comes to you from dignitaries who are institutions on their own in chromatography purification and related.
URL:http://www.pharmajournalist.com/event/purify-chromatography-purification-conclave/
LOCATION:Taj Skyline\, Ahmedabad
ORGANIZER;CN="Custage Marketing Solutions LLP":MAILTO:rashi@custage.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221213
DTEND;VALUE=DATE:20221215
DTSTAMP:20260515T234251
CREATED:20220909T103058Z
LAST-MODIFIED:20220909T103058Z
UID:35114-1670889600-1671062399@www.pharmajournalist.com
SUMMARY:Advanced Wound Care Summit Europe 2022
DESCRIPTION:The Advanced Wound Care Summit EU is the first industry-led\, EU-focused\, forum on commercialising innovative wound care products. How will you comply with the EU MDR? What is the best strategy to ensure widespread clinical adoption and reimbursement? What can you do to engage with other wound care companies\, for collaboration or acquisition? Expect to hear from\, and network with\, wound care leaders\, across large wound care companies and SMEs. \nFind out how C-level Executives\, VPs and Directors of R&D are tackling the most pressing industry challenges\, seizing growth opportunities\, and building innovation. Whether an executive\, investor\, researcher or healthcare professional\, this meeting offers an empowering environment that allows you to secure your stake in the AWC market. \nTo know more visit: https://hubs.ly/Q01lR8NX0
URL:http://www.pharmajournalist.com/event/advanced-wound-care-summit-europe-2022/
LOCATION:TBC\, Berlin\, Germany
ORGANIZER;CN="Kisaco Research":MAILTO:Jodie.purser@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221213
DTEND;VALUE=DATE:20221216
DTSTAMP:20260515T234251
CREATED:20220822T112559Z
LAST-MODIFIED:20221018T100720Z
UID:34982-1670889600-1671148799@www.pharmajournalist.com
SUMMARY:2nd Synthetic Biology-Based Therapies Summit
DESCRIPTION:Returning for a second year the Synthetic Biology-Based Therapies Summit is the leading industry-defining forum made exclusively for leaders in the synthetic and engineered biology space\, focusing on the technical challenges that lie ahead in the path towards commercialization. \nDownload the event guide to find out more \nLearn from industry trailblazers at Arsenal Biosciences\, bit.bio\, Moderna\, MIT\, Novome Bio\, Strand Therapeutics\, Synlogic and more\, to support your efforts in developing safe and effective synthetic biology-based therapeutics. \nJoin Global Innovators to: \n\nLearn from the academics that are driving the future of synthetic biology development with the National Institute of Standards & Technology and Massachusetts Institute of Technology\nLeverage novel control strategies for improved therapeutic efficacy and patient safety with Arsenal Biosciences\, bit.bio\, CHAIN Biotechnology and Strand Therapeutics\nEmploy synthetic biology techniques in the clinic\, hearing about a variety of therapeutic applications with Kite Pharma: A Gilead Company\, Novome Biotechnologies and Senti Biosciences\nApply computation\, artificial intelligence\, and machine learning to engineered and synthetic biology with Lawrence Berkley National Laboratory and Sanofi\nExplore the potential for engineered biology as a tool for drug discovery and development with LifeMine Therapeutics and Merck & Co.
URL:http://www.pharmajournalist.com/event/2nd-synthetic-biology-based-therapies-summit/
LOCATION:(exact venue TBC)\, Boston\, US.
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221213
DTEND;VALUE=DATE:20221216
DTSTAMP:20260515T234251
CREATED:20220728T084521Z
LAST-MODIFIED:20220728T084521Z
UID:34801-1670889600-1671148799@www.pharmajournalist.com
SUMMARY:5th Annual RNA-Targeted Drug Discovery Summit
DESCRIPTION:RNA-Targeted Drug Discovery Summit returns for its fifth year this December. Join the summit for deep dive into new and emerging topics such as: \n\nInduced Proximity as a new class of “targeted RNA degraders”\nNext-generation probing and screening technologies to accelerate HIT identification and validation\nBiophysical\, biochemical\, and cell-based assay development strategies to identify and optimize small molecules interacting with RNA\nIn vivo pharmacology\, safety\, and efficacy early considerations to accelerate the transition from discovery to pre-clinical and clinical development\n\nView the event program here: https://ter.li/7qs017 \nSecure your place here: https://ter.li/jlh128 \nIf you have any further questions regarding the summit\, please contact us at info@hansonwade.com.
URL:http://www.pharmajournalist.com/event/5th-annual-rna-targeted-drug-discovery-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221207
DTEND;VALUE=DATE:20221209
DTSTAMP:20260515T234251
CREATED:20220727T082442Z
LAST-MODIFIED:20220727T082442Z
UID:34784-1670371200-1670543999@www.pharmajournalist.com
SUMMARY:3rd TIGIT Axis Therapies Summit
DESCRIPTION:In the context of a need to regroup and accelerate practice-changing cancer immunotherapies towards approval and to patients in need\, the 3rd TIGIT Axis Therapies Summit returns to reunite large pharma\, innovative biotechs and pioneering academics to discuss the full range of next-generation TIGIT axis targeted drug modalities and maximize TIGIT-axis targeting in the solid tumor\, blood cancer and non-oncology setting. \nCovering deciphering the mechanistic intricacies underlying TIGIT axis signaling\, defining combination partners that improve efficacy and strengthen TIGIT targeted pipelines\, exploring novel drug designs in terms of Fc functionality and IgG type\, identifying molecular signatures relevant to the tumor microenvironment and periphery to incorporating unique pharmacology properties into trial design\, this is your comprehensive guide for addressing the unique challenges of TIGIT axis targeted drug development and powering up your pipelines. \nThis year’s sharp two-day agenda leans into the clinical headwinds faced by so many immune checkpoint targets. As the space regroups\, join the conversation to build meaningful partnerships and maximize the clinical and commercial success of the next generation of TIGIT axis targeted drugs. \nFind out more here: https://ter.li/ir0syg
URL:http://www.pharmajournalist.com/event/3rd-tigit-axis-therapies-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221206
DTEND;VALUE=DATE:20221208
DTSTAMP:20260515T234251
CREATED:20221110T115946Z
LAST-MODIFIED:20221110T115946Z
UID:35768-1670284800-1670457599@www.pharmajournalist.com
SUMMARY:2nd Next-Generation Food Allergy Drug Development Summit
DESCRIPTION:The field of food allergy therapeutics is continuing to boom as companies flood the news with fresh IND clearances and clinical readouts. The race to market for the next food allergy therapy is well and truly on\, but access to funding and large patient cohorts\, along with the need for novel IgE biomarkers and better diagnostics (to name a few challenges) are holding drug developers back from even faster progress. \nThe 2nd Next-Generation Food Allergy Drug Development Summit is reuniting this December as the only industry-focused meeting dedicated to unveiling the complexities of food allergies with novel oral immunotherapies\, antibody-based therapeutics and microbiome-based approaches to accelerate ground-breaking treatments for the ever-increasing unmet medical need. \nJoin us in-person for the first time in Boston as the food allergy community comes together to unravel the complex regulatory landscape\, identify and validate novel clinical biomarkers to aid patient selection and explore novel routes of administration to innovate long-lasting\, next-generation treatments. \nTo know more visit: https://bit.ly/3GlzzRp
URL:http://www.pharmajournalist.com/event/2nd-next-generation-food-allergy-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221206
DTEND;VALUE=DATE:20221209
DTSTAMP:20260515T234251
CREATED:20221024T225543Z
LAST-MODIFIED:20221025T102843Z
UID:35606-1670284800-1670543999@www.pharmajournalist.com
SUMMARY:4th Annual Targeted Radiopharmaceuticals Summit Europe
DESCRIPTION:The long-awaited 4th Annual Targeted Radiopharmaceuticals Summit Europe is returning in-person in Amsterdam on December 6-8\, 2022! \nAs the only devoted meeting for large pharma\, biotech and pioneering academics\, this meeting unites key stakeholders under the mutual and ambitious objective of advancing radioligand candidates to commercialisation through rigorous clinical rationale and reliable supply chain design. \nDownload the full Event Guide to learn what the 29+ expert speakers will present on\, including: \n\n\n\nMeeting the newest contenders to enter the field including Ariceum Therapeutics and TRIMT\nDiscovering new targeting systems that are opening avenues to treating more cancers with Tagworks and Ratio Therapeutics\nGetting the most up-to-date information on current radionuclide stocks and how the world’s leading isotope producers are increasing their production and variety of products with Duke University\nEnhancing your trial design to conduct the most rigorous trials with help from leading clinical stage companies with Oncoinvent\nThe ability to showcase your work and meet new people across dedicated sessions and have the meetings that will help you build vital collaborations\n\n\n\nAccess the official Event Guide here to see the complete agenda and speaker line up.
URL:http://www.pharmajournalist.com/event/4th-annual-targeted-radiopharmaceuticals-summit-europe/
LOCATION:Leonardo Royal Amsterdam\, Paul van Vlissingenstraat 24\, Amsterdam\, 1096 BK\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221206
DTEND;VALUE=DATE:20221209
DTSTAMP:20260515T234251
CREATED:20220914T121744Z
LAST-MODIFIED:20220914T121744Z
UID:35170-1670284800-1670543999@www.pharmajournalist.com
SUMMARY:5th Commercializing Clinically Validated Digital Therapeutics Summit
DESCRIPTION:The 5th Commercializing Clinically Validated Digital Therapeutics Summit\, designed with DTx companies\, pharma and clinicians\, will return this December to address the industry’s major challenges such as improving user experience\, clinical trial development\, and standing out in a crowded market through open discussion and case-study led presentations.   \nWhether you’re a veteran at commercializing clinically validated digital therapeutics\, looking for partnerships\, or a new entrant to the field\, you’ll leave this conference with practical lessons and essential connections needed to supercharge DTx commercial ambitions across 2022 and beyond. \nTo know more visit: https://ter.li/5e6hqd
URL:http://www.pharmajournalist.com/event/5th-commercializing-clinically-validated-digital-therapeutics-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221205
DTEND;VALUE=DATE:20221208
DTSTAMP:20260515T234251
CREATED:20220919T115535Z
LAST-MODIFIED:20220919T115535Z
UID:35224-1670198400-1670457599@www.pharmajournalist.com
SUMMARY:4th Annual Cell Therapy Analytical Development Summit
DESCRIPTION:Cell Therapy Analytical Development Summit US is back for its fourth year\, taking place in Boston (December 5-7). Join 180+ colleagues from analytical development\, process development\, quality control and regulatory affairs\, to standardize analytical testing and take advantage of unrivalled content across: \n\n3-days\n6 deep-dive workshops\n2 tracks\n\nSeize an unmatched opportunity to delve into cell potency\, safety\, viability\, sterility and more across both autologous and allogeneic cell therapy products. \nPlease use this URL – https://ter.li/ghwxjk
URL:http://www.pharmajournalist.com/event/4th-annual-cell-therapy-analytical-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221205
DTEND;VALUE=DATE:20221209
DTSTAMP:20260515T234251
CREATED:20220819T112000Z
LAST-MODIFIED:20220819T112000Z
UID:34927-1670198400-1670543999@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy for Neurological Disorders
DESCRIPTION:Delivering the Next Wave of Gene Therapies to the CNS \nWith systemic toxicity challenges plaguing the AAV field\, direct administration for CNS indications creates an ideal target for gene therapy. This is an exciting year for the neurological space with clinical data to show and new biotechs coming out of the woodwork to release the next wave of gene therapies with more advanced CNS targeting for a wider selection of neurological targets. \nThe 4th Annual Gene Therapy for Neurological Disorders Summit will unite gene therapy developers with an industry-focused agenda across 4 days and 2 dedicated tracks of content to solve the preclinical\, translational and clinical challenges of targeting a wide range of neurodevelopmental and neurodegenerative disorders with both ‘first’ and ‘next’ generation gene therapies. \nJoin the expanding audience of gene therapy experts to: \n\nStreamline CNS drug delivery devices for improved brain biodistribution\nDiscover novel vectors for CNS specificity & tropism\nOptimize gene therapy strategy for pediatric & adult neurological disorders\n\nTo know more visit: https://ter.li/rluqrj
URL:http://www.pharmajournalist.com/event/4th-annual-gene-therapy-for-neurological-disorders/
LOCATION:The Westin Seaport District\, 425 Summer St\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221201
DTEND;VALUE=DATE:20221203
DTSTAMP:20260515T234251
CREATED:20220923T091314Z
LAST-MODIFIED:20220923T091314Z
UID:35230-1669852800-1670025599@www.pharmajournalist.com
SUMMARY:PAT & Real Time Quality Summit
DESCRIPTION:The time has come to remove the pharmaceutical industry’s reliance on archaic off-line testing and embrace the cost and speed-to-market savings of online control and real-time product quality. \nThe PAT market is projected to reach USD 4.96 Billion by 2027\, spurred on by the recent ICH Q14/ Q2 (R2) guidelines\, there has never been a more opportune moment to leverage regulator’s support of QbD\, real-time control\, and process intervention to achieve meaningful business impact in your organization\, through reduced downtime\, manufacturing footprint\, ease of scale-up and product consistency for approval. \nWhether you’re applying in small molecules\, biologics\, or ATMP\, bridge the gap in technology\, culture\, or regulatory experience that is the bottleneck to your organization saving an average 50% reduction in process cycle time and winning speed to market\, with the strategical implementation of smart process analytical technologies and quality by control (QbC). \nJoin a senior community of experts in process development\, manufacturing\, regulatory & quality to understand how to monitor critical quality attributes with reactive and predictive control systems and discover novel PAT technologies as the industry moves the needle toward realizing real-time release. \nTo know more visit: https://ter.li/080rbc
URL:http://www.pharmajournalist.com/event/pat-real-time-quality-summit/
LOCATION:Hilton San Diego Gaslamp Quarter\, 401 K Street\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221129
DTEND;VALUE=DATE:20221202
DTSTAMP:20260515T234251
CREATED:20220824T095329Z
LAST-MODIFIED:20220824T114844Z
UID:34996-1669680000-1669939199@www.pharmajournalist.com
SUMMARY:3rd CRISPR 2.0 Summit
DESCRIPTION:Recognized with a Nobel Prize in 2020\, CRISPR has opened the floodgates for a new era of gene editing therapies\, promising to transform genetic disease treatments. With a well-established early field of genomics research\, drug developers and researchers have been busy establishing the next-generation CRISPR toolkit\, including Cas nucleases\, base and prime editing technologies\, and innovative delivery platforms. \nThe 3rd CRISPR 2.0 Summit is devoted to showcasing the latest and greatest innovations by uncovering how the next generation of CRISPR tools are radically enhancing efficacy\, minimizing off-target effects & enabling efficient tissue-specific delivery to help you progress your program into and through the clinic. \nAcross three days of content\, co-designed with 27+ industry thought leaders\, this streamlined one-track summit will unite 100+ key players in the CRISPR space\, from large pharma to ground-breaking biotech\, academics to exciting service providers\, all with the purpose of paving a way forward to market for your CRISPR gene editing program. \nHere’s a snapshot of our 27+ thought leaders: \n\nKiran Musunuru\, Professor of Medicine\, Perelman School of Medicine\, University of Pennsylvania\nAmy Simon\, Chief Medical Officer\, Beam Therapeutics\nJane Grogan\, Chief Scientific Officer\, Graphite Bio\nLiron Walsh\, Head of Development; In Vivo Programs\, Intellia Therapeutics\nJeremy Duffield\, Chief Scientific Officer\, Prime Medicine\nEric B. Kmiec\, Executive Director & Chief Scientific Officer\, Christiana Care Gene Editing Institute\nRafi Emmanuel\, Senior Vice President – Research & Development\, Emendo Biotherapeutics\nJohn Murphy\, Chief Scientific Officer\, Arbor Biotechnologies\nInge Yung-Chih Cheng\, Principal Scientist\, Pfizer\nJoey Riepsaame\, Head of Genome Engineering\, University of Oxford\nRammohan Devulapally\, Principal Scientist\, GenEdit\n\nBe part of the community as we dive deep into: \n\nRefining non-viral tissue targeted CRISPR delivery methods for maximized safety and efficacy\, with help from GenEdit and the latest research from the David Liu Lab.\nFrom bench to bedside: translating basic CRISPR research into a viable therapeutic product\, with Beam Therapeutics\nLeverage the latest base and prime editing technology for enhanced precision treatment of inherited disorders\, with Prime Medicine and UC Irvine.\n\nAnd more! \nJoin this unmissable summit and network experts from the likes of Beam Therapeutics\, The David Liu Lab\, Pfizer\, GenEdit\, AZ\, GSK\, Caribou Biosciences\, Prime Medicine\, Intellia Therapeutics and many more. \nTo know more visit: https://ter.li/vumobp
URL:http://www.pharmajournalist.com/event/3rd-crispr-2-0-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221129
DTEND;VALUE=DATE:20221202
DTSTAMP:20260515T234251
CREATED:20220811T093818Z
LAST-MODIFIED:20220815T091224Z
UID:34899-1669680000-1669939199@www.pharmajournalist.com
SUMMARY:6th Obesity & NASH Drug Development Summit
DESCRIPTION:The first wave of investment in NASH is dispersing in the wake of highly demanding biopsy endpoints\, but opportunities to target obesity and metabolic syndrome are catalyzing increasing excitement. Pivotal readouts in GLP-1 receptor agonists and exciting progress in regenerative medicine and microRNAs are redefining the drug development landscape for metabolic disorders. \n \nWith mounting competition for the market in obesity and all eyes on the next wave of NASH candidates\, the 6th Obesity & NASH Drug Development Summit\, (previously the NASH Summit) is dedicated to reuniting industry leaders in metabolic syndrome to consolidate targets directly implicated in disease pathology and traverse the regulatory hurdles to commercialization. \nJoin 150+ industry pioneers in Boston including pioneers Novo Nordisk\, Eli Lilly\, Boehringer Ingelheim\, Pfizer\, Inventiva\, Regeneron\, FDA\, AstraZeneca\, and more to advance your pipeline towards approved treatment. \nAccess the official event guide here to learn more.
URL:http://www.pharmajournalist.com/event/6th-obesity-nash-drug-development-summit/
LOCATION:Revere Boston Common\, 200 Stuart St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221129
DTEND;VALUE=DATE:20221202
DTSTAMP:20260515T234251
CREATED:20220811T093237Z
LAST-MODIFIED:20220811T093237Z
UID:34895-1669680000-1669939199@www.pharmajournalist.com
SUMMARY:4th Inflammasome Therapeutics Summit
DESCRIPTION:The 4th Inflammasome Therapeutics Summit is the only industry-led forum uniting large pharma\, biotechs\, and academic KOLs\, with the common goal of accelerating the practical translation and clinical development of inflammasome-targeted drugs\, which are shaking up the immunology R&D landscape. \nAs the space eagerly awaits data readouts from proof-of-concept trials\, and with more companies than ever before with active inflammasome therapeutic pipelines; this is your opportunity to be involved in interactive discussions on: \n\nDeciphering the intricate mechanisms underlying dysregulated inflammasome signaling within the wider context of the immune system \nOvercoming limitations of preclinical models\, identifying clinically meaningful biomarkers of inflammasome inhibition\, and defining good clinical endpoints \nTaming inflammation and achieving optimized safety profiles using the next frontier for inflammasome-targeted drugs including those targeting NLRP3 and novel targets \nDelving into specific disease groups to demonstrate where inflammasome therapeutics will be most impactful\n\nJoin 120+ fellow peers and industry heavyweights this Fall including NodThera\, Novartis\, Zyversa Therapeutics\, and more\, to build meaningful partnerships and propel the next frontier of inflammasome therapeutics from pipeline development into a clinical and commercial reality. \nAccess the official event guide here to learn more.
URL:http://www.pharmajournalist.com/event/4th-inflammasome-therapeutics-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221128
DTEND;VALUE=DATE:20221201
DTSTAMP:20260515T234251
CREATED:20220819T112405Z
LAST-MODIFIED:20220819T112405Z
UID:34933-1669593600-1669852799@www.pharmajournalist.com
SUMMARY:2nd Rare CNS & Neurodevelopmental Drug Development Summit
DESCRIPTION:Developing New Outcome Measures\, Functional Biomarkers & Clinical Research Regulatory Frameworks for Disease-Modifying Therapeutics Across Neurodevelopmental & Rare\, Genetic CNS Disorders \nWith more clinical data emerging\, neurodevelopmental drug development is advancing from hypotheticals to real-life clinical results\, outcomes\, and functional biomarkers\, catapulting this critical field forwards. \nJoin 100+ peers this November at the 2nd Rare CNS & Neurodevelopmental Drug Development Summit – the only industry dedicated drug development forum for large pharma\, biotech\, academia\, and patient advocacy groups\, paving the way towards symptomatic and successful disease modifying treatments. \nTightly focused on industry progress\, stakeholders will explore ASOs\, gene therapies and small molecules across autistic syndromes and seizure phenotypes at this unique drug sponsor conference. \nDon’t miss out on this definitive opportunity to collaborate with patient groups and gain regulatory clarity on clinical trial design\, endpoints and delivery and toxicity concerns as well as deep diving into functional and molecular biomarkers\, emerging therapeutic targets and translational biology. \nIf you are working towards treatments for rare CNS and neurodevelopmental disorders\, including (but not limited to) Angelman Syndrome\, Rett syndrome\, Fragile X\, Dravet Syndrome and CDKL5 Syndrome or discovering new frontiers in anti-epileptic therapeutics\, this is the platform you need. \nTo know more visit: https://ter.li/9yzux5
URL:http://www.pharmajournalist.com/event/2nd-rare-cns-neurodevelopmental-drug-development-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221128
DTEND;VALUE=DATE:20221202
DTSTAMP:20260515T234251
CREATED:20220720T112134Z
LAST-MODIFIED:20220720T112134Z
UID:34732-1669593600-1669939199@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy Analytical Development Summit 2022
DESCRIPTION:The past twelve months have culminated in an unprecedented level of excitement\, investment\, and clinical progress within the gene therapy field. As the field strives to strike a delicate balance between safety and efficacy\, in the context of increased regulatory scrutiny and safety challenges\, attending the 4th Annual Gene Therapy Analytical Development as an analytical scientist has never been so important. \nThis year’s summit returns in-person to Boston to reunite 300+ analytical experts in innovative biotech\, pharma and academia to continue to develop resilient\, long-lasting and robust analytical tools to enhance the safety\, quality and efficacy of gene therapy products.   \nWhether you are focusing on specific characterization methods\, enhancing your genome sequencing\, advancing your understanding of full and partial particles\, or advancing your early-stage bioassays\, with 4 tracks\, 8 pre-conference workshops and a post-conference focus day\, the 4th Gene Therapy Analytical Development Summit will encompass all aspects of analytical development\, giving you the chance to address and overcome challenges. \nIf you work in quality control\, quality assurance\, or process development – we’ve listened and we’ve answered. This year’s agenda includes a novel track designed for quality control and process development groups working in gene therapy. Talks include enhancing the knowledge transfer between departments\, bridging between analytical methods with regards to QC/PD\, and enhancing in-process development support. \nWhether you’re working with AAV\, non-viral vectors or lentiviral vectors\, this is your opportunity to enhance your existing analytical methods and explore innovative new tools to support safe and effective gene therapy development. \nTo know more visit: https://ter.li/w2diiu
URL:http://www.pharmajournalist.com/event/4th-annual-gene-therapy-analytical-development-summit-2022/
LOCATION:Westin Boston Seaport\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221116
DTEND;VALUE=DATE:20221118
DTSTAMP:20260515T234251
CREATED:20221024T222603Z
LAST-MODIFIED:20221024T222746Z
UID:35596-1668556800-1668729599@www.pharmajournalist.com
SUMMARY:Liquid Biopsy Surveillance & Early Detection Summit
DESCRIPTION:Recognize Disease Hallmarks Earlier for Improved Patient Outcomes \nGain Clarity Across Next Generation Non-Invasive Testing Technologies Revolutionizing Cancer Monitoring\, MRD & Earlier Detection to Support Novel Pre-Metastatic Drug Development with Maximized Access \nIn the wake of new FDA guidance and exciting MRD partnership announcements between Grail & AstraZeneca\, Amgen & Bristol Myers Squibb the liquid biopsy industry is experiencing a paradigm shift. Touted as having the potential to transform clinical practice as we know it\, technical progress and mounting investment in premetastatic applications are creating huge industry-wide excitement for liquid biopsy-based screening & surveillance for novel precision drug development. \nWith technology maturity on the near horizon\, the inaugural Liquid Biopsy Surveillance & Early Detection Summit is your only dedicated platform providing much-needed clarity on the industry’s emerging assays increasingly opening the doors to novel trial design and better patient outcomes. \nAs drug & diagnostic developers look to realize the commercial impact of early detection & MRD while shifting pipelines from the metastatic setting\, here lies your best opportunity to harness game-changing technologies to define leading stratification\, surrogate endpoint\, and regulatory strategies – accelerating the delivery of breakthrough therapies into the clinic. \nProviding a path forward for early detection & surveillance to become a widespread patient reality\, unite with 80+ Translational\, Biomarker\, Clinical\, Regulatory\, Precision Medicine\, Medical Affairs & Diagnostic experts at your only forum prioritizing liquid biopsy applications for earlier intervention. \nTo know more visit: https://ter.li/0kjtfi
URL:http://www.pharmajournalist.com/event/liquid-biopsy-surveillance-early-detection-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221116
DTEND;VALUE=DATE:20221118
DTSTAMP:20260515T234251
CREATED:20220805T095510Z
LAST-MODIFIED:20220805T095849Z
UID:34850-1668556800-1668729599@www.pharmajournalist.com
SUMMARY:Microbiome Connect: USA 2022
DESCRIPTION:The 7th Annual Microbiome Connect: USA 2022 is dedicated to showcasing the leading drug development platforms applying microbes\, microbe modulators and microbial-derived components to prevent or treat human diseases or make medical diagnosis. As the first FDA approved microbiome-targeted therapeutic emerges\, drug developers will have the opportunity to benchmark their rational drug platforms\, targeting validated pathways in gastrointestinal\, neurological\, metabolic disorders\, as well as oncology-based indications. Furthermore\, the manufacturing challenges associated with reaching commercialization specific to microbiome-based drugs will be addressed in depth. With talks from Live Biotherapeutic Product manufacturing experts\, including the Head of CBER\, on topics including how to handle USP 61/62\, and achieving co-culturing capabilities. Join us to hear from microbiome biotechs\, pharma voices\, investment bodies\, and more on how to develop robust\, scalable\, and reproducible formulations for microbe-derived/-targeting products entering late-stage investigations and reaching for the market. \nTo know more visit: www.microbiomeconnectusa.com
URL:http://www.pharmajournalist.com/event/microbiome-connect-usa-2022/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221114
DTEND;VALUE=DATE:20221116
DTSTAMP:20260515T234251
CREATED:20220609T062845Z
LAST-MODIFIED:20220609T062845Z
UID:34376-1668384000-1668556799@www.pharmajournalist.com
SUMMARY:Medical Devices and IVD 2022
DESCRIPTION:SAE Media Group’s Inaugural Conference… \nMedical Devices and IVD 2022\n14 – 15 November 2022\nLondon\, UK\nwww.medicaldevices-ivd.com/PJ \nNavigating The MDR and IVDR and Best Strategies for Compliance  \nSAE Media Group is proud to announce the launch of the Medical Devices and IVD Conference\, taking place on 14 – 15 November 2022 in London\, UK. \n \nThe MDR implementation last May has highlighted issues within the industry that need to be addressed and the upcoming IVDR updates will have a profound impact on the medical device industry\, bringing certain products into regulatory scope that were previously excluded\, introducing new manufacturing requirements\, and increasing the burden for post-market surveillance. \nThe conference will provide insight into the latest updates in EU MDR and IVDR regulations and will discuss strategies for how to best comply with these regulations. In addition\, the conference will consider the evolving regulatory landscape for digital health software. \nBENEFITS OF ATTENDING: \n\nEngage with notified body and competent authority representatives addressing key MDR and IVDR requirements\nGain insights from pharma regulatory experts in compliance and companion diagnostics\nUnderstand the latest guidance on IVD Regulations to overcome common challenges\, in addition to considering evolving global regulations\nExamine post-market expectations for surveillance and vigilance of your medical devices\nDelve into advancements in the digitalisation of medical devices and the regulatory considerations surrounding this\n\nWHO SHOULD ATTEND: \nExecutives\, Directors\, VPs\, Heads\, Principals\, Managers of: \n\nDevice Manufacturing\nRegulatory Affairs\nIVDR\nMDR\nCMC\nCompliance\nRisk Management\nTraceability\nVigilance\nProduct Development\nPFS\nCombination Products\n\nTo find out more\, please visit: www.medicaldevices-ivd.com/PJ \nEARLY BIRD RATES: \n\nBOOK BY 30TH JUNE TO SAVE £200\nBOOK BY 30TH SEPTEMBER TO SAVE £100\n\nADDITIONAL CONTACT INFORMATION: \n\nE: ngaloria@smi-online.co.uk\nT: +44 (0) 20 7827 6164\n\nFOLLOW US ON: \n\nTwitter: @SAEMGPharma\n\nLinkedIn: SAE Media Group Pharma
URL:http://www.pharmajournalist.com/event/medical-devices-and-ivd-2022/
LOCATION:London\, UK
ORGANIZER;CN="SAE Media Group":MAILTO:ngaloria@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221109
DTEND;VALUE=DATE:20221112
DTSTAMP:20260515T234251
CREATED:20220728T083732Z
LAST-MODIFIED:20220728T083732Z
UID:34796-1667952000-1668211199@www.pharmajournalist.com
SUMMARY:6th Antifibrotic Drug Development Summit (AFDD)
DESCRIPTION:Returning for the 6th year\, the Antifibrotic Drug Development Summit (AFDD) will host the transferrable insights you need from IPF\, NASH\, CKD and more in one place at one time\, so you can advance the progress of your antifibrotic therapies. \nFrom exploring cellular mechanisms to identify a common fibrotic pathway to bridging the translational gap to prove early therapeutic effectiveness; this unique cross-organ\, cross-disease\, cross-discipline discussion forum is here to transform your fibrosis research. \nJoin 100+ industry super giants from Boehringer Ingelheim\, Genentech\, Gilead\, Pfizer\, Novartis\, and many more in Boston to harness the knowledge you need for your 2022/23 antifibrotic research and drug development. \nTo know more visit: https://ter.li/u60ni5
URL:http://www.pharmajournalist.com/event/6th-antifibrotic-drug-development-summit-afdd/
LOCATION:Crowne Plaza Woburn\, 15 Middlesex Canal Park Rd\, Woburn\, MA\, 01801\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR